ライフサイエンスコーパス: heterologous antigen

1 red immune responses to both live vector and heterologous antigen.

2 the vector would not limit expression of the heterologous antigen.

3 ease-causing meningococci expressing vaccine-heterologous antigens.

4 oliferation in response to both parasite and heterologous antigens.

5 d are being developed as vaccine vectors for heterologous antigens.

6 homologous strains but only a 70K band using heterologous antigens.

7 a vector for the expression and delivery of heterologous antigens.

8 cessfully to improve immune responses toward heterologous antigens.

9 ped as vaccine vectors for the expression of heterologous antigens.

10 accines, as cloning hosts and as carriers of heterologous antigens.

11 ease-causing meningococci expressing vaccine-heterologous antigens.

12 the homologous antigens than those with the heterologous antigens.

13 o induce antibody responses to the expressed heterologous antigen after oral or intranasal immunizati

14 es expression of virulence genes and encoded heterologous antigens (Ags) in appropriately engineered

15 ne response against both the live vector and heterologous antigen and, as occurs following oral inocu

16 ic IgGs could react to homologous as well as heterologous antigens and parasites, suggesting that con

17 vector strains to effect secretion of large heterologous antigens and that a V. cholerae vector stra

18 ngendering immune responses against both the heterologous antigens and vector strain.

19 and may provide a means by which to deliver heterologous antigens and/or immune modulators of the in

20 esented and processed in a manner similar to heterologous antigen, and with differences in the mechan

21 their variable domain to express epitopes of heterologous antigens-antigenized antibodies-function as

22 studies on RASV development differ on where heterologous antigens are expressed and localized within

23 e optimal promoter for in vivo expression of heterologous antigens by live, attenuated vaccine vector

24 optimal protective immunity to homologous or heterologous antigens by oral, intranasal, or intraperit

25 r the regulated delayed in vivo synthesis of heterologous antigens by vaccine strains.

26 However, synthesis of sufficient levels of heterologous antigen can result in an increase in metabo

27 ng, including live vector systems expressing heterologous antigens, conjugation of antigen to carrier

28 In this study, the benefit of having a heterologous antigen expressed on the surface of a live

29 detect immune responses directed against the heterologous antigens expressed at low levels in any gro

30 ion and immunization, including responses to heterologous antigens expressed by cholera vector strain

31 ttenuated vaccine strains or as vehicles for heterologous antigen expression.

32 nto host cells, have been adapted to deliver heterologous antigens for vaccine development.

33 vector (BRD509) to immunize mice against the heterologous antigen fragment C (FrgC).

34 Sheaths displaying heterologous antigens generated better immune responses

35 mutation in a Salmonella vaccine to deliver heterologous antigens has not yet been investigated.

36 immune responses directed against expressed heterologous antigens have been developed.

37 stomatitis virus (VSV) vectors that express heterologous antigens have shown promise as vaccines in

38 ials of S. enterica serovar Typhi expressing heterologous antigens have shown that few subjects have

39 icited effective priming of CD8 T cells to a heterologous antigen in mice.

40 uced a specific immune response against this heterologous antigen in mice.

41 ) autotransporter system for accumulation of heterologous antigens in cell culture supernatant.

42 been developed that allow the expression of heterologous antigens in commensal Gram-positive bacteri

43 expression from plasmids of at least certain heterologous antigens in such strains.

44 two strains contain genes encoding different heterologous antigens in the chromosome of the vaccine v

45 a novel export system for the expression of heterologous antigens in the supernatant of attenuated S

46 We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiot

47 ng their effects on the immune response to a heterologous antigen, ovalbumin.

48 ed in the presence of autologous, as well as heterologous, antigen-presenting cells, suggesting a MHC

49 Live attenuated bacterial strains expressing heterologous antigens represent an attractive vaccine de

50 tibody responses were stimulated to both the heterologous antigen rPspA and Salmonella lipopolysaccha

51 d to compare the immune responses to the two heterologous antigens, StxB1 and EaeA, expressed by thes

52 been used extensively to express and deliver heterologous antigens to host mucosal tissues.

53 lts demonstrate the possibility of targeting heterologous antigens to specific cellular compartments

54 n to be functional and capable of delivering heterologous antigens to the class I antigen presentatio

55 lla typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system followin

56 (CPDs) are known to ferry covalently linked heterologous antigens to the intracellular compartment b

57 rains is a promising strategy for presenting heterologous antigens to the mammalian immune system to

58 bility of live Salmonella vectors to deliver heterologous antigens to the mammalian immune system.

59 d IgG2a pattern was observed for the carried heterologous antigen, which displayed a dominant IgG1 re

60 Thus, subsequent challenges with heterologous antigens, which themselves induce memory CT

61 r findings show that a strategy of combining heterologous antigen with self-antigens could produce a